Having trouble accessing articles? Reset your cache.

Cellectar, Novelos deal

Cancer company Novelos acquired radiopharmaceutical company Cellectar in a stock deal valued at $64.4 million based on Novelos' close of

Read the full 202 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE